|
US5858980A
(en)
*
|
1990-03-30 |
1999-01-12 |
Autoimmune, Inc. |
Peptide fragments of myelin basic protein
|
|
US7090982B2
(en)
|
1991-10-22 |
2006-08-15 |
The Governors Of The University Of Alberta |
Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
|
|
US6252040B1
(en)
|
1991-10-22 |
2001-06-26 |
The Governors Of The University Of Alberta |
Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
|
|
IL113812A
(en)
|
1994-05-24 |
2000-06-29 |
Yeda Res & Dev |
Copolymer-1 pharmaceutical compositions containing it and its use
|
|
US5858964A
(en)
*
|
1995-04-14 |
1999-01-12 |
Yeda Research And Development Co. Ltd. |
Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
|
|
IL119989A0
(en)
*
|
1997-01-10 |
1997-04-15 |
Yeda Res & Dev |
Pharmaceutical compositions for oral treatment of multiple sclerosis
|
|
HUP0100891A2
(hu)
*
|
1998-02-13 |
2001-06-28 |
Autoimmune, Inc. |
A COP-1 és Th2 fokozó citokinek gyógyászati alkalmazása
|
|
EP1105414A2
(en)
|
1998-07-23 |
2001-06-13 |
President And Fellows of Harvard College |
Synthetic peptides and methods of use for autoimmune disease therapies
|
|
ES2527760T3
(es)
*
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
|
|
CA2337688C
(en)
|
1998-07-23 |
2016-04-05 |
Yeda Research And Development Co., Ltd. |
Treatment of autoimmune conditions with copolymer 1 and related copolymers
|
|
US6800287B2
(en)
*
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
JP4629229B2
(ja)
|
1998-09-25 |
2011-02-09 |
イエダ リサーチ アンド デベロップメント カンパニー リミテッド |
分子量マーカーとして用いるため、また治療用途のための共重合体１関連ポリペプチド
|
|
US6514938B1
(en)
|
1998-09-25 |
2003-02-04 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
WO2000020010A1
(en)
*
|
1998-10-02 |
2000-04-13 |
Yeda Research And Development Co., Ltd. |
Alternate day administration of copolymer 1 for treating autoimmune diseases
|
|
US7083777B1
(en)
|
1999-04-02 |
2006-08-01 |
The Brigham And Women's Hospital, Inc. |
Immunomodulating polymers
|
|
ES2243450T3
(es)
*
|
2000-01-20 |
2005-12-01 |
Yeda Research And Development Co. Ltd. |
El uso de copolimero 1 y peptidos y polipeptidos relacionados, y de celulas t tratadas con los mismos, para terapia neuroprotectora.
|
|
WO2005046719A1
(en)
|
2003-11-12 |
2005-05-26 |
Yeda Research And Development Co. Ltd. |
Vaccine and method for treatment of neurodegenerative diseases
|
|
US7022663B2
(en)
*
|
2000-02-18 |
2006-04-04 |
Yeda Research And Development Co., Ltd. |
Oral, nasal and pulmonary dosage formulations of copolymer 1
|
|
AU3846901A
(en)
*
|
2000-02-18 |
2001-08-27 |
Yeda Res & Dev |
Oral, nasal and pulmonary dosage formualtions of copolymer 1
|
|
US20020077278A1
(en)
*
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
IL153236A0
(en)
*
|
2000-06-05 |
2003-07-06 |
Teva Pharma |
The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
MXPA02007109A
(es)
*
|
2000-06-07 |
2002-12-13 |
Yeda Res & Dev |
El uso del copolimero 1 y peptidos y polipeptidos relacionados y celulas t tratadas con estos para proteger a las celulas del sistema nervioso central de la toxicidad del glutamato.
|
|
AU6887101A
(en)
*
|
2000-06-20 |
2002-01-02 |
Caprion Pharmaceuticals, Inc. |
Copolymers and methods of treating prion-related diseases
|
|
WO2002076503A1
(en)
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Treatment of central nervous system diseases by antibodies against glatiramer acetate
|
|
IL137460A0
(en)
|
2000-07-24 |
2001-07-24 |
Yeda Res & Dev |
Identifying antigen clusters for monitoring a global state of an immune system
|
|
US20040037828A1
(en)
|
2002-07-09 |
2004-02-26 |
Bar-Ilan University |
Methods and pharmaceutical compositions for healing wounds
|
|
SV2003000753A
(es)
|
2000-12-05 |
2003-06-16 |
Brigham & Womens Hospital |
Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
|
|
KR100442122B1
(ko)
*
|
2001-07-31 |
2004-07-30 |
한국전기연구원 |
영구 자석을 이용한 브러시리스 발전기
|
|
JP4369234B2
(ja)
*
|
2001-12-04 |
2009-11-18 |
テバ ファーマシューティカル インダストリーズ リミティド |
グラチラマー・アセテートの強度の測定のための方法
|
|
CN102151330B
(zh)
*
|
2001-12-06 |
2017-04-12 |
耶达研究及发展有限公司 |
治疗运动神经元疾病的疫苗和方法
|
|
WO2003059387A2
(en)
*
|
2001-12-21 |
2003-07-24 |
Ilex Oncology, Inc. |
Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
|
|
CA2411786C
(en)
|
2002-11-13 |
2009-01-27 |
Brantford Chemicals Inc. |
A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
|
|
ATE548045T1
(de)
|
2003-01-07 |
2012-03-15 |
Yeda Res & Dev |
Vakzine in augentropfenform enthaltend copolymer 1 für die therapeutische immunisierung
|
|
PT1592384E
(pt)
*
|
2003-01-21 |
2013-01-28 |
Yeda Res & Dev |
Cop-1 para o tratamento de doenças inflamatórias do intestino
|
|
EP1603530A1
(en)
*
|
2003-03-04 |
2005-12-14 |
Teva Pharmaceutical Industries Limited |
Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
|
|
AU2004227852B2
(en)
|
2003-03-31 |
2010-01-14 |
The Brigham And Women's Hospital, Inc. |
Zwitterionic immunomodulators for the treatment of asthma and allergy
|
|
EP1680087A1
(en)
*
|
2003-10-31 |
2006-07-19 |
Teva Pharmaceutical Industries Limited |
Nanoparticles for drug delivery
|
|
EP1701730B1
(en)
|
2003-12-09 |
2013-08-21 |
Yeda Research And Development Co., Ltd. |
Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders
|
|
CA2556152A1
(en)
*
|
2004-02-02 |
2005-08-18 |
Mixture Sciences, Inc. |
Peptide mixtures with immunomodulatory activity
|
|
WO2005085323A2
(en)
*
|
2004-03-01 |
2005-09-15 |
Peptimmune, Inc. |
Methods and compositions for treatment of autoimmune diseases
|
|
WO2005084377A2
(en)
*
|
2004-03-03 |
2005-09-15 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and riluzole
|
|
US20050260770A1
(en)
*
|
2004-04-01 |
2005-11-24 |
Cohen Irun R |
Antigen array and diagnostic uses thereof
|
|
WO2005120542A2
(en)
|
2004-05-07 |
2005-12-22 |
Peptimmune, Inc. |
Methods of treating disease with random copolymers
|
|
US20060194725A1
(en)
*
|
2004-05-07 |
2006-08-31 |
James Rasmussen |
Methods of treating disease with random copolymers
|
|
US7655221B2
(en)
*
|
2004-05-07 |
2010-02-02 |
Peptimmune, Inc. |
Methods of treating disease with random copolymers
|
|
US20060229233A1
(en)
|
2004-06-25 |
2006-10-12 |
Id Biomedical Corporation |
Compositions and methods for treating neurological disorders
|
|
DK1797109T3
(en)
*
|
2004-09-09 |
2016-04-11 |
Yeda Res & Dev |
MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
|
|
US7495072B2
(en)
*
|
2004-09-09 |
2009-02-24 |
Teva Pharmaceutical Industries, Ltd. |
Process for preparation of mixtures of polypeptides using purified hydrobromic acid
|
|
CA2583589C
(en)
*
|
2004-10-29 |
2012-04-24 |
Sandoz Ag |
Processes for preparing glatiramer
|
|
US8324641B2
(en)
*
|
2007-06-29 |
2012-12-04 |
Ledengin, Inc. |
Matrix material including an embedded dispersion of beads for a light-emitting device
|
|
CA2588908C
(en)
*
|
2004-11-29 |
2014-09-23 |
Yeda Research And Development Co. Ltd |
Induction of neurogenesis and stem cell therapy in combination with copolymer 1
|
|
ZA200705874B
(en)
*
|
2005-02-02 |
2009-04-29 |
Teva Pharma |
Process for producing polypeptide mixtures using hydrogenolysis
|
|
US20100167983A1
(en)
*
|
2007-10-22 |
2010-07-01 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
|
ES2420404T3
(es)
*
|
2005-02-17 |
2013-08-23 |
Teva Pharmaceutical Industries Ltd. |
Terapia de combinación con acetato de glatiramero y rasagilina para el tratamiento de esclerosis múltiple
|
|
WO2006116602A2
(en)
*
|
2005-04-25 |
2006-11-02 |
Yeda Research And Development Company |
Markers associated with the therapeutic efficacy of glatiramer acetate
|
|
WO2007081975A2
(en)
*
|
2006-01-11 |
2007-07-19 |
Teva Pharmaceutical Industries, Ltd. |
Method of treating multiple sclerosis
|
|
US8206726B2
(en)
|
2006-02-06 |
2012-06-26 |
The Brigham And Women's Hospital, Inc. |
Zwitterionic polysaccharides for promotion of immune system maturation and health
|
|
AU2007238595A1
(en)
|
2006-04-13 |
2007-10-25 |
Peptimmune, Inc. |
Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
|
|
EP2013628B1
(en)
*
|
2006-04-28 |
2016-01-06 |
Momenta Pharmaceuticals, Inc. |
Methods of evaluating peptide mixtures
|
|
KR100831796B1
(ko)
*
|
2006-05-29 |
2008-05-28 |
엘지전자 주식회사 |
타임 쉬프트 기능을 내장한 영상표시기기 및 그 재생 방법
|
|
EP2046366B1
(en)
|
2006-06-28 |
2016-08-31 |
Yeda Research And Development Company Limited |
Copolymer-1 for treatment of age-related macular degeneration
|
|
DE602007003848D1
(de)
*
|
2006-07-05 |
2010-01-28 |
Momenta Pharmaceuticals Inc |
Verbessertes verfahren zur herstellung von copolymer-1
|
|
EP2381254B2
(en)
|
2007-06-21 |
2017-07-19 |
Momenta Pharmaceuticals, Inc. |
Copolymer assay
|
|
US20090029766A1
(en)
*
|
2007-07-26 |
2009-01-29 |
Lutnick Howard W |
Amusement gaming access and authorization point
|
|
EP2173766A1
(en)
*
|
2007-07-31 |
2010-04-14 |
Natco Pharma Limited |
Process for the preparation glatiramer acetate (copolymer-1)
|
|
AP3467A
(en)
|
2007-10-16 |
2015-11-30 |
Peptimmune Inc |
Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
|
|
EP2217250A4
(en)
|
2007-11-09 |
2011-01-05 |
California Inst Of Techn |
IMMUNOMODULATING COMPOUNDS AND RELEVANT COMPOSITIONS AND METHODS
|
|
BRPI0819001A2
(pt)
*
|
2007-11-28 |
2014-10-07 |
Teva Pharma |
"método para retardar o acesso de esclerose múltipla clinicamente defenitiva em um paciente correndo o risco de desenvolver clinicamente a esclerose múltipla definitiva, método para reduzir a progressão da atividade de doença monitorada por imagem latente de ressonância magnética (mri) em um paciente correndo o risco de desenvolver clinicamente a esclerose múltipla definitiva, método para reduzir a progressão dos sintomas de esclerose múltipla definitiva em um paciente, método para reduzir a freqüência de recidiva em um paciente que experimentou um ataque clínico simples sugestivo de esclerose múltipla e que tem pelo menos uma lesão sugestiva de esclerose múltipla, método para retardar a progressão para a esclerose múltipla clinicamente definitiva em um paciente que apresenta um primeiro evento clínico sugestivo de esclerose múltipla e pelo menos uma lesão sugestiva de esclerose múltipla, uso de acetato de glatiramer e acetato de glatiramer
|
|
EP2277050B2
(en)
*
|
2008-04-16 |
2022-09-28 |
Momenta Pharmaceuticals, Inc. |
Analysis of amino acid copolymer compositions
|
|
US8399600B2
(en)
*
|
2008-08-07 |
2013-03-19 |
Sigma-Aldrich Co. Llc |
Preparation of low molecular weight polylysine and polyornithine in high yield
|
|
AU2009279636A1
(en)
*
|
2008-08-07 |
2010-02-11 |
Scinopharm Taiwan, Ltd. |
Synthesis of glatiramer acetate
|
|
AR074881A1
(es)
|
2008-12-24 |
2011-02-16 |
Synthon Bv |
Un proceso para purificar una mezcla de polimeros
|
|
RU2011144566A
(ru)
*
|
2009-04-03 |
2013-05-10 |
Момента Фармасьютикалз, Инк. |
Контроль сополимерных композиций
|
|
AU2009347384B2
(en)
|
2009-06-04 |
2014-10-23 |
Council Of Scientific & Industrial Research |
A process for the preparation of copolymer - 1 (Cop-I), composed of L-alanine, L-lysine, L-glutamic acid and L-tyrosine-drug for the treatment of multiple sclerosis
|
|
ES2383347T3
(es)
*
|
2009-07-15 |
2012-06-20 |
Teva Pharmaceutical Industries, Ltd. |
Formulación de volumen reducido de acetato de glatirámero y procedimientos de administración
|
|
US8920373B2
(en)
|
2009-07-15 |
2014-12-30 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
|
US8691790B2
(en)
*
|
2009-07-27 |
2014-04-08 |
James Layne Boucher |
Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
|
|
EP2405749B1
(en)
|
2009-08-20 |
2013-05-08 |
Yeda Research and Development Co., Ltd. |
Low frequency glatiramer acetate therapy
|
|
US8377885B2
(en)
|
2010-01-04 |
2013-02-19 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
|
HRP20182076T1
(hr)
|
2010-01-04 |
2019-02-08 |
Mapi Pharma Limited |
Sustav s kontroliranim otpuštanjem koji obuhvaća glatiramer acetat
|
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
|
US20130035390A1
(en)
|
2010-01-13 |
2013-02-07 |
Ramot At Tel-Aviv University Ltd. |
Treatment of multiple sclerosis
|
|
US8759302B2
(en)
*
|
2010-03-16 |
2014-06-24 |
Teva Pharmaceutical Industries, Ltd. |
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
|
|
DK2555753T3
(en)
|
2010-04-07 |
2018-11-26 |
California Inst Of Techn |
Vesicle for delivering a compound to a mucosal membrane as well as corresponding compositions, methods and systems
|
|
RU2012150443A
(ru)
*
|
2010-04-27 |
2014-06-10 |
Др. Редди'С Лабораторис Лтд. |
Получение полипептидов и их солей
|
|
WO2011146910A1
(en)
|
2010-05-20 |
2011-11-24 |
Round June L |
Antigen specific tregs and related compositions, methods and systems
|
|
EP2598889A4
(en)
|
2010-07-29 |
2014-01-22 |
Reddys Lab Ltd Dr |
MOLECULAR WEIGHT MARKER FOR GLATIRAMERACETATE
|
|
BR112013008573A2
(pt)
|
2010-10-11 |
2016-07-12 |
Teva Pharma |
citocinas biomarcadoras como indicadores de resposta clínica a acetato de glatirâmer.
|
|
CA2827275A1
(en)
|
2011-02-14 |
2012-09-20 |
Usv Limited |
Copolymer-1, process for preparation and analytical methods thereof
|
|
EP2699317B1
(en)
|
2011-04-21 |
2016-08-10 |
Mapi Pharma Limited |
Random pentapolymer for treatment of autoimmune diseases
|
|
US20140348861A1
(en)
|
2011-05-05 |
2014-11-27 |
National Institute Of Immunology |
Synthetic peptides and random copolymers for the treatment of autoimmune disorders
|
|
WO2013009864A1
(en)
|
2011-07-11 |
2013-01-17 |
Momenta Pharmaceuticals, Inc. |
Structure assessment of heterogeneous polypeptide mixtures
|
|
WO2013009885A2
(en)
|
2011-07-11 |
2013-01-17 |
Momenta Pharmaceuticals, Inc. |
Evaluation of copolymer diethylamide
|
|
EP2731617A4
(en)
|
2011-07-12 |
2015-07-01 |
Brigham & Womens Hospital |
LIPID-BASED PSA COMPOSITIONS, METHOD FOR THEIR INSULATION AND USE METHOD THEREFOR
|
|
US8575198B1
(en)
|
2011-09-07 |
2013-11-05 |
Momenta Pharmaceuticals, Inc. |
In-process control for the manufacture of glatiramer acetate
|
|
CN103957705A
(zh)
|
2011-10-10 |
2014-07-30 |
泰华制药工业有限公司 |
适用于预测对醋酸格拉替雷的临床反应的单核苷酸多态性
|
|
EP2642290A1
(en)
|
2012-03-19 |
2013-09-25 |
Synthon BV |
Glatiramer acetate human monocytic cell line-based potency assay
|
|
WO2013139728A1
(en)
|
2012-03-19 |
2013-09-26 |
Synthon Bv |
Glatiramer acetate human monocyte cell-based potency assay
|
|
US20140045740A1
(en)
*
|
2012-08-13 |
2014-02-13 |
Momenta Pharmaceuticals, Inc. |
Analysis of glatiramer acetate
|
|
MX2015004563A
(es)
|
2012-10-10 |
2015-07-14 |
Teva Pharma |
Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
|
|
WO2014060942A2
(en)
*
|
2012-10-20 |
2014-04-24 |
Mahesh Kandula |
Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
|
|
WO2014128079A1
(en)
|
2013-02-19 |
2014-08-28 |
Synthon B.V. |
Glatiramer acetate multidose formulation
|
|
RS53779B1
(sr)
|
2013-03-08 |
2015-06-30 |
Teva Pharmaceutical Industries Ltd. |
Injekcioni uređaj za višekratnu upotrebu za špric
|
|
DK2774639T3
(en)
|
2013-03-08 |
2015-01-12 |
Teva Pharma |
Reusable injection device for a syringe
|
|
EP2971173A4
(en)
|
2013-03-14 |
2016-11-23 |
Mylan Inc |
GLATIRAMERACETATREAKTIONSBIOMARKER-mRNA-POTENCY ASSAY
|
|
WO2014173463A1
(en)
|
2013-04-26 |
2014-10-30 |
Synthon Bv |
Glatiramer acetate human monocytic cell line-based potency assay
|
|
JP2016521284A
(ja)
|
2013-05-10 |
2016-07-21 |
カリフォルニア インスティチュート オブ テクノロジー |
大腸ガンのプロバイオティクスによる防止および処置
|
|
CN103265624B
(zh)
*
|
2013-05-27 |
2015-04-22 |
成都圣诺生物制药有限公司 |
格拉替雷的制备方法
|
|
CN104371012A
(zh)
*
|
2013-08-12 |
2015-02-25 |
深圳翰宇药业股份有限公司 |
一种合成醋酸格拉替雷的方法
|
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
|
CA2928084A1
(en)
|
2013-10-24 |
2015-04-30 |
Mylan Inc. |
Human t cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
|
|
JP2017503169A
(ja)
|
2013-12-31 |
2017-01-26 |
イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド |
オリゴヌクレオチド抗原を使用する全身性エリテマトーデスの診断
|
|
BR112016020919A2
(pt)
|
2014-03-12 |
2018-01-23 |
Yeda Res & Dev |
redução dos níveis ou da atividade sistêmica de células t regulatórias para o tratamento de doença e lesão do snc
|
|
CN104844697B
(zh)
|
2014-09-26 |
2018-10-23 |
深圳翰宇药业股份有限公司 |
醋酸格拉替雷的制备方法
|
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|
|
US11047855B2
(en)
|
2015-03-01 |
2021-06-29 |
Immunarray Ltd. |
Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
|
|
WO2016201342A1
(en)
|
2015-06-10 |
2016-12-15 |
California Institute Of Technology |
Sepsis treatment and related compositions methods and systems
|
|
CN108135167B
(zh)
|
2015-08-19 |
2021-07-09 |
哈佛学院院长及董事 |
脂化psa组合物和方法
|
|
ES2744179T3
(es)
|
2015-09-24 |
2020-02-24 |
Chemi Spa |
Análisis de la distribución de peso molecular de mezclas de polipéptidos complejas
|
|
EP3170836B1
(en)
|
2015-11-23 |
2018-10-24 |
Chemi SPA |
Rp-hplc analysis of complex polypeptide mixtures
|
|
CN107522774B
(zh)
*
|
2016-06-22 |
2021-07-02 |
深圳翰宇药业股份有限公司 |
一种醋酸格拉替雷制备过程中哌啶残留量的实时控制方法
|
|
WO2018002930A1
(en)
|
2016-06-30 |
2018-01-04 |
Stem Cell Medicine Ltd. |
Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
|
|
EP3484441A4
(en)
|
2016-07-15 |
2020-03-18 |
President and Fellows of Harvard College |
GLYCOLIPID COMPOSITIONS AND METHOD FOR USE
|
|
US12097292B2
(en)
|
2016-08-28 |
2024-09-24 |
Mapi Pharma Ltd. |
Process for preparing microparticles containing glatiramer acetate
|
|
CN109689082A
(zh)
|
2016-08-28 |
2019-04-26 |
Mapi医药公司 |
用于制备包含醋酸格拉替雷的微粒的方法
|
|
FI3506921T3
(fi)
|
2016-08-31 |
2023-07-21 |
Mapi Pharma Ltd |
Glatirameeriasetaattia käsittäviä depot-järjestelmiä
|
|
MX2019010174A
(es)
|
2017-03-26 |
2019-10-15 |
Mapi Pharma Ltd |
Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple.
|
|
CA3062964C
(en)
|
2017-05-15 |
2024-11-12 |
Mapi Pharma Ltd. |
TREATMENT OF MULTIPLE SCLEROSIS WITH A LONG-ACTING GLATIRAMER AND ADIPE-DERIVED STEM CELLS
|
|
AU2018270396B2
(en)
|
2017-05-15 |
2025-03-20 |
Stem Cell Medicine Ltd. |
Treatment of multiple sclerosis with adipose-derived stem cells
|
|
EP3765034A1
(en)
|
2018-03-12 |
2021-01-20 |
Yeda Research and Development Co. Ltd |
Treatment of a heart disease
|